Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_assertion type Assertion NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_head.
- NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_assertion description "[The activation of this pathway explains the use of both VEGF and VEGF-receptor inhibitors (bevacizumab, sunitinib and sorafenib) in the therapy of advanced CCRCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_provenance.
- NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_assertion evidence source_evidence_literature NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_provenance.
- NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_assertion SIO_000772 20437403 NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_provenance.
- NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_assertion wasDerivedFrom befree-2016 NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_provenance.
- NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_assertion wasGeneratedBy ECO_0000203 NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_provenance.